TDP-43, explained — and what's being tested against it
A calm, sourced tracker of research on TDP-43, the protein that goes wrong in nearly all cases of ALS. Plain English first; the science is one tap away.
- Nucleus
- nuclear pore
- TDP-43
- RNA
- TDP-43 depleted
- TDP-43 clumps
- P = phosphorylated
- TDP-43
What is TDP-43?
TDP-43 is a protein your cells make from a gene called TARDBP[1]. Normally it lives in the cell's nucleus (its control center), where it grabs onto RNA — the working copies of genes — and helps edit them correctly.
In ALS, TDP-43 leaves the nucleus and clumps together in the surrounding cell. This was discovered in 2006[2]. Those clumps are found in about 97% of people with ALS and about 45% of people with frontotemporal dementia (FTD)[3]. That includes most people with ALS who have no known genetic cause.
So there are two problems: the clumps may be toxic, and the nucleus loses TDP-43's editing work. When that editing stops, some genes pick up junk pieces called cryptic exons[4]. Two important examples:
- STMN2 (stathmin-2) helps nerve fibers grow and repair. Without TDP-43, STMN2 is badly made and levels drop[5][6].
- UNC13A helps nerve cells pass signals across synapses. Without TDP-43 it is also mis-made, and common gene variants that raise ALS risk make this worse[7][8].
Because these broken pieces show up only when TDP-43 isn't working, researchers are using them both as biomarkers (signs you can measure) and as drug targets: several drugs now in trials try to put STMN2 or UNC13A back.
Deeper dive: the molecular details
TDP-43 (TAR DNA-binding protein 43) is a 414-amino-acid heterogeneous nuclear ribonucleoprotein encoded by TARDBP on chromosome 1[1]. It has an N-terminal domain that self-associates, two RNA-recognition motifs (RRM1, RRM2) that bind UG-rich RNA, and a C-terminal low-complexity (prion-like) domain where most disease mutations cluster[9].
In ALS/FTLD-TDP, TDP-43 is depleted from the nucleus and forms cytoplasmic inclusions that are hyperphosphorylated, ubiquitinated and cleaved into C-terminal fragments[2]. Dominant TARDBP mutations cause a small fraction of familial ALS[9], showing that TDP-43 dysfunction can be causal, not just a bystander.
Loss of nuclear TDP-43 de-represses poorly conserved cryptic exons[4]. In STMN2, a cryptic exon in intron 1 with a premature polyadenylation site produces a truncated transcript and loss of stathmin-2[5][6]. In UNC13A, cryptic exon inclusion triggers nonsense-mediated decay; ALS/FTD risk SNPs in the same intron potentiate inclusion[7][8]. Antisense oligonucleotides that block these cryptic splice sites are in clinical trials (see the pipeline).
The numbers “~97% of ALS / ~45% of FTD” are autopsy-based estimates summarized by Ling, Polymenidou & Cleveland (2013)[3]. Exceptions include SOD1- and FUS-related ALS, which usually lack TDP-43 inclusions.
What's new
- November 16, 2026 Pipeline update: QRL-201QRL-201: status changed from Active, not recruiting; open-label extension ongoing; pivotal trial (CONQUR, ~270 participants per ENCALS 2026 abstract) expected to start in 2027 (QurAlis Sept 2026 deck calls it a pivotal Phase 2b) to Active, not recruiting (ANQUR); fully moved to open-label extended dosing in Canada, the UK and the EU; FDA cleared the US IND on Nov 16 2026, allowing the pivotal CONQUR trial, planned to start in H1 2027 (no NCT ID yet; ~270 participants per ENCALS 2026 abstract)
- November 16, 2026 New paper: Cholesterol dysmetabolism in motor neurons drives ALS pathogenesis.Morimoto S, Takahashi S, Okano H · Rinsho shinkeigaku = Clinical neurology · added to PubMed 2026-11-16
- November 16, 2026 Pipeline update: QRL-201QRL-201 (QurAlis): FDA cleared the US IND for QRL-201, allowing the pivotal CONQUR trial, planned to start in H1 2027. Company-reported final ANQUR dose-range results (not peer reviewed; 69 participants): 50% slower ALSFRS-R progression vs placebo at 10 mg (Day 253, p<0.05); CSF pNfH down 46% from baseline at 3 mg (Day 197, p<0.01); plasma NfL fell in both dose groups; no serious adverse events reported in the dose-range phase.
- November 13, 2026 Pipeline update: NUZ-001 (monepantel)NUZ-001 (monepantel): status changed from Fully enrolled; active, not recruiting; ~240 participants (estimated); topline expected late Q2 2027 to Fully enrolled; active, not recruiting; 250 participants at 78 US sites per the company (ClinicalTrials.gov still lists 240 estimated); first participant entered the Active Treatment Extension on Nov 13 2026; topline expected late Q2 2027
- November 13, 2026 Pipeline update: NUZ-001 (monepantel)NUZ-001 (monepantel) (Neurizon Therapeutics): First participant in HEALEY Regimen I entered the Active Treatment Extension. Neurizon says the trial is fully enrolled with 250 participants at 78 US sites (ClinicalTrials.gov still lists 240 estimated); topline still expected late Q2 2027.
- November 12, 2026 Pipeline update: BIIB147BIIB147: status changed from Recruiting (HORIZON; Washington University in St. Louis and Austin Neuromuscular Center); ~69 participants (estimated); started Oct 7 2026 to Recruiting (HORIZON; Washington University in St. Louis, Austin Neuromuscular Center, and HonorHealth Neurology in Scottsdale, AZ); ~69 participants (estimated); started Oct 7 2026
- November 12, 2026 New paper: Neuronal cell-cycle re-entry stratifies clinical trajectories in amyotrophic lateral sclerosis.Plessis-Belair J, Sher RB · Brain : a journal of neurology · added to PubMed 2026-11-12
- November 11, 2026 New paper: UNC13A splice correction rescues synaptic dysfunction induced by TDP-43 loss.Keuss MJ, Harley P, Ryadnov E et al. · Nature · added to PubMed 2026-11-11
On this site
- Pipeline — 14 programs that target TDP-43 or its downstream effects.
- Trials — 28 ALS studies that explicitly mention TDP-43, TARDBP, STMN2, UNC13A or related terms.
- Biomarkers — how TDP-43 problems can be measured.
- Papers — 48 recent PubMed papers.
- Explainer videos — short plain-English videos about recent papers, each with its script and the original citation.
- Glossary & resources.
Sources
- NCBI Gene: TARDBP (Gene ID 23435)
- Neumann et al., Science 2006 (PMID 17023659)
- Ling, Polymenidou & Cleveland, Neuron 2013 (PMID 23931993)
- Ling et al., Science 2015 (PMID 26250685)
- Klim et al., Nat Neurosci 2019 (PMID 30643292)
- Melamed et al., Nat Neurosci 2019 (PMID 30643298)
- Ma et al., Nature 2022 (PMID 35197626)
- Brown et al., Nature 2022 (PMID 35197628)
- Sreedharan et al., Science 2008 (PMID 18309045)